Gallant Builds First Ultra-Low-Temp Vet Cold Chain With MWI Ahead of Stem Cell Launch

New updates have been reported about Gallant.

Gallant has signed a landmark fulfillment agreement with MWI Animal Health to create what they describe as the first ultra-low temperature cold chain in veterinary medicine, positioning the company for the anticipated launch of its lead off-the-shelf stem cell therapy. The logistics platform, centered on -80°C storage and overnight distribution from MWI’s Edwardsville, Kansas facility, is designed to support national and select noncontiguous U.S. markets, including Alaska, Hawaii, and Puerto Rico.

The partnership directly underpins Gallant’s pipeline, led by sonruvetcel injectable suspension, a uterine-derived allogeneic mesenchymal stromal cell therapy being developed for cats with refractory feline chronic gingivostomatitis and currently under regulatory review for potential conditional approval by the FDA Center for Veterinary Medicine. By securing scalable, precision cold-chain infrastructure in advance of approval, Gallant is reducing a key commercialization risk and aligning its regenerative medicine platform with veterinary practice needs, as reflected in survey data showing most veterinarians expect stem cell therapy to become standard care and are more likely to adopt off-the-shelf, IV-delivered products.

Gallant’s CEO, Dr. Linda Black, emphasized that the MWI agreement is intended to ensure that, once approved, veterinarians can reliably access an FDA-regulated stem cell therapy with consistent quality and integrity. For Gallant, the arrangement provides a distribution blueprint that can be extended to additional disease-modifying stem cell products targeting inflammatory and degenerative conditions in companion animals, enabling faster market penetration without building proprietary logistics at scale.

MWI’s planned investment in ultra-low temperature logistics specific to veterinary clinics is expected to lower barriers to adoption by handling complex storage and handling requirements on behalf of practices. Strategically, this deal positions Gallant at the center of an emerging category in animal health, coupling first-mover product potential with first-mover infrastructure, and could materially influence the company’s revenue trajectory and valuation if FDA conditional approval and subsequent market uptake are achieved.

While sonruvetcel remains an investigational new animal drug pending regulatory clearance, the cold chain build-out suggests Gallant is preparing for near-term commercialization and broader portfolio expansion. For investors and partners, the agreement signals that Gallant is moving beyond pure R&D into an execution phase that integrates manufacturing, regulatory, and last-mile delivery capabilities, potentially establishing a defensible competitive moat in veterinary regenerative medicine.

Survey work conducted by Gallant with the American Animal Hospital Association, indicating high intent among veterinarians to recommend stem cell therapies when available in off-the-shelf formats, further supports the demand thesis underpinning this logistics investment. Overall, the MWI alliance appears to be a critical enabler of Gallant’s strategy to turn its scientific assets into a scalable business, with the cold chain infrastructure likely to be as central to its long-term economics as the therapies themselves.